한빛사논문
- 조회585
Sang Hoon Yeon, M.D.a, Hyo Jin Lee, M.D., Ph.D.b,*
aChungnam National University Hospital, Daejeon, South Korea
bChungnam National University College of Medicine, Daejeon, South Korea
*Correspondence
Abstract
TO THE EDITOR
When reporting the clinical benefits of enfortumab vedotin as compared with standard chemotherapy in the EV-301 trial, Powles et al. (March 25 issue)1 indicated that enfortumab vedotin was associated with significantly longer survival and a higher overall response in patients with advanced urothelial carcinoma who had previously received treatment with a platinum-containing agent and a programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor. Although the treatment-related events specific to enfortumab vedotin were generally mild to moderate and manageable, we are concerned about respiratory toxicity. In the trial, pneumonia and dyspnea were adverse events occurring during the treatment period that caused deaths in the enfortumab vedotin group.1 In addition, respiratory failure and interstitial lung disease causing treatment-related deaths were reported in patients treated with enfortumab in the EV-101 and EV-201 trials.2,3 Since nectin-4, a therapeutic target of enfortumab, is expressed in epithelial cells of the nasopharynx and trachea and in lung macrophages,4 patients may be at risk for the emergence of respiratory toxicity. It would be useful to assess the large prospective data set from Powles et al. in this context. We would like to have detailed information on any adverse respiratory events.
논문정보
- Correspondence
- 2021년 07월 (BRIC 등록일 2021-07-05)
- 국내 연구진
- 의약학 > 종양의학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
